Merck, known as MSD outside the US and Canada, has commenced a Phase II/III study of MK-8931 for the treatment of Alzheimer’s disease.
The Phase II/III trial will assess the safety and efficacy profile of MK-8931, an investigational oral ß-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, against a placebo.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Merck Research Laboratories neuroscience and ophthalmology senior vice president and head Dr Darryle Schoepp said; "This new study is an important step in our overall strategy to understand the potential of the BACE inhibitor mechanism and MK-8931, our lead compound, in multiple stages of Alzheimer’s disease."
EPOCH multi-centre, randomised study will initially assess the MK-8931 safety profile in a 200 patient cohort prior to advancing into a larger Phase III study.
The 78-week, placebo-controlled, Phase II/III trial will assess one of three oral doses in strengths 12mg, 40mg and 60 mg of MK-8931 for efficacy and safety against placebo when administered daily.
The parallel-group, double-blind study is expected to enrol around 1,700 patients in the main Phase III cohort.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe change from baseline in the Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and the change from baseline in the Alzheimer’s Disease Cooperative Study, Activities of Daily Living (ADCS-ADL) score will be the primary efficacy outcomes.
MK-8931 demonstrated reduction in cerebral spinal fluid ß-amyloid by more than 90% in healthy volunteers, without dose limiting side effects in a multiple dose Phase I study.
